Conformis Transformation Taking Longer Than Expected
The company declined in the low-single digits for 3Q22 as Conformis' business model transition meets roadblocks. Nov 07, 2022
OrthoPediatrics Lowers Guidance on RSV Disruption
The company lowered its 2022 guidance despite nearly 40% growth in 3Q as RSV infections reduce pediatric surgical capacity. Nov 04, 2022
SeaSpine’s New Distributors Drive Record Revenues
The company grew nearly 45% in 3Q22 on the strength of its new distribution partners and increased surgical volumes. Nov 04, 2022
Zimmer Biomet Momentum Leads to Guidance Raise
The company grew in the mid-single digits for 3Q22 when adjusting for currency headwinds and raised its 2022 revenue guidance. Nov 03, 2022
Stryker Maintains Strong Growth Outlook
Stryker reported 3Q22 orthopedic sales of $2.26 billion, +4.8% compared to the third quarter of 2021. The company expects inflationary... Nov 02, 2022
CONMED Sees Diminishing Upside for Late-2022
The company's 3Q22 orthopedic sales grew in the low double-digits, fueled by the recent acquisitions of In2Bones and Biorez. Oct 28, 2022
Orthopedic Enabling Technology Sales
We take a fresh look at 2021 orthopedic sales by market category with the inclusion of our new Enabling Technology reporting segment. Oct 26, 2022
DePuy Synthes’ Gains Offset by Currency Headwinds
The company rebounded nicely in 3Q22 with mid-single digit growth when excluding foreign currency headwinds. Oct 19, 2022
NASS 2022: A Conversation with ZimVie
We spoke to the company about its progress in untangling itself from Zimmer Biomet, OUS markets and ZimVie’s medium-term priorities. Oct 19, 2022
Introducing Our Enabling Technology Segment
We estimate the orthopedic enabling technology generated $1.64 billion in sales for 2021 as the industry moves toward digital solutions. Oct 11, 2022
